(firstQuint)A Phase 2/3 Study of TVP-1012 at 0.

5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants.

 This is a multicenter, randomized, double-blind, placebo-controlled, parallel group, phase 2/3 study to evaluate the efficacy and safety of TVP-1012 as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.

 The study period will consist of a 28-week trial period.

 The participants who fulfill the inclusion criteria and do not meeting any of the exclusion criteria will be enrolled, and randomized in a 1:1:1 ratio to the 0.

5 mg of TVP-1012, the 1 mg of TVP-1012, or the placebo group.

 In each treatment group, participants will receive 0.

5 mg of TVP-1012, 1 mg of TVP-1012, or placebo once daily in a double-blinded manner.

.

 A Phase 2/3 Study of TVP-1012 at 0.

5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants@highlight

The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (0.

5 mg or 1 mg/day) as an add-on to levodopa in Japanese participants with Parkinson's disease with wearing-off phenomenon.

